...
search icon
sybx-img

Synlogic Inc, Common Stock

SYBX

NAQ

$1.401

-$0.01

(-0.71%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$16.49M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.81
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.22 L
$2.04 H
$1.401

About Synlogic Inc, Common Stock

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSYBXSectorS&P500
1-Week Return0.71%0.57%0.11%
1-Month Return-2.08%3.31%1.23%
3-Month Return-2.41%3.04%3.39%
6-Month Return-4.73%-4.66%9.31%
1-Year Return-23.37%1.44%22.95%
3-Year Return-95.18%15.75%42.13%
5-Year Return-96.58%42.42%81.24%
10-Year Return-99.81%103.96%189.66%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.22M545.00K1.75M1.18M3.37M[{"date":"2019-12-31","value":65.97,"profit":true},{"date":"2020-12-31","value":16.17,"profit":true},{"date":"2021-12-31","value":52.03,"profit":true},{"date":"2022-12-31","value":35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue---5.67M5.29M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.4,"profit":true}]
Gross Profit2.22M545.00K1.75M(4.49M)3.37M[{"date":"2019-12-31","value":65.97,"profit":true},{"date":"2020-12-31","value":16.17,"profit":true},{"date":"2021-12-31","value":52.03,"profit":true},{"date":"2022-12-31","value":-133.17,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%(380.42%)100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-380.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses56.63M61.01M62.52M68.60M58.53M[{"date":"2019-12-31","value":82.56,"profit":true},{"date":"2020-12-31","value":88.94,"profit":true},{"date":"2021-12-31","value":91.14,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":85.32,"profit":true}]
Operating Income(54.41M)(60.47M)(60.77M)(67.42M)(55.16M)[{"date":"2019-12-31","value":-5440900000,"profit":false},{"date":"2020-12-31","value":-6046600000,"profit":false},{"date":"2021-12-31","value":-6076500000,"profit":false},{"date":"2022-12-31","value":-6741900000,"profit":false},{"date":"2023-12-31","value":-5516100000,"profit":false}]
Total Non-Operating Income/Expense6.08M2.59M412.00K2.54M296.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":42.6,"profit":true},{"date":"2021-12-31","value":6.78,"profit":true},{"date":"2022-12-31","value":41.75,"profit":true},{"date":"2023-12-31","value":4.87,"profit":true}]
Pre-Tax Income(51.37M)(59.17M)(60.56M)(66.15M)(57.27M)[{"date":"2019-12-31","value":-5137300000,"profit":false},{"date":"2020-12-31","value":-5917300000,"profit":false},{"date":"2021-12-31","value":-6056100000,"profit":false},{"date":"2022-12-31","value":-6614700000,"profit":false},{"date":"2023-12-31","value":-5726800000,"profit":false}]
Income Taxes(2.70M)(2.64M)(2.44M)(1.27M)14.00K[{"date":"2019-12-31","value":-19300,"profit":false},{"date":"2020-12-31","value":-18828.57,"profit":false},{"date":"2021-12-31","value":-17450,"profit":false},{"date":"2022-12-31","value":-9085.71,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(48.67M)(56.54M)(58.12M)(64.88M)(57.28M)[{"date":"2019-12-31","value":-4867100000,"profit":false},{"date":"2020-12-31","value":-5653700000,"profit":false},{"date":"2021-12-31","value":-5811800000,"profit":false},{"date":"2022-12-31","value":-6487500000,"profit":false},{"date":"2023-12-31","value":-5728200000,"profit":false}]
Income From Continuous Operations(51.37M)(59.17M)(60.56M)(66.15M)(59.44M)[{"date":"2019-12-31","value":-5137300000,"profit":false},{"date":"2020-12-31","value":-5917300000,"profit":false},{"date":"2021-12-31","value":-6056100000,"profit":false},{"date":"2022-12-31","value":-6614700000,"profit":false},{"date":"2023-12-31","value":-5944400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(48.67M)(56.54M)(58.12M)(64.88M)(57.28M)[{"date":"2019-12-31","value":-4867100000,"profit":false},{"date":"2020-12-31","value":-5653700000,"profit":false},{"date":"2021-12-31","value":-5811800000,"profit":false},{"date":"2022-12-31","value":-6487500000,"profit":false},{"date":"2023-12-31","value":-5728200000,"profit":false}]
EPS (Diluted)(1.72)(1.64)(1.14)(0.93)(4.72)[{"date":"2019-12-31","value":-172,"profit":false},{"date":"2020-12-31","value":-164,"profit":false},{"date":"2021-12-31","value":-114,"profit":false},{"date":"2022-12-31","value":-93,"profit":false},{"date":"2023-12-31","value":-472,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SYBX
Cash Ratio 2.54
Current Ratio 2.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SYBX
ROA (LTM) -35.95%
ROE (LTM) -131.58%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SYBX
Debt Ratio Lower is generally better. Negative is bad. 0.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SYBX
Trailing PE NM
Forward PE NM
P/S (TTM) 5.94
P/B 1.24
Price/FCF NM
EV/R 0.35
EV/Ebitda 0.18

FAQs

What is Synlogic Inc share price today?

Synlogic Inc (SYBX) share price today is $1.401

Can Indians buy Synlogic Inc shares?

Yes, Indians can buy shares of Synlogic Inc (SYBX) on Vested. To buy Synlogic Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SYBX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Synlogic Inc be purchased?

Yes, you can purchase fractional shares of Synlogic Inc (SYBX) via the Vested app. You can start investing in Synlogic Inc (SYBX) with a minimum investment of $1.

How to invest in Synlogic Inc shares from India?

You can invest in shares of Synlogic Inc (SYBX) via Vested in three simple steps:

  • Click on Sign Up or Invest in SYBX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Synlogic Inc shares
What is Synlogic Inc 52-week high and low stock price?

The 52-week high price of Synlogic Inc (SYBX) is $2.04. The 52-week low price of Synlogic Inc (SYBX) is $1.22.

What is Synlogic Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Synlogic Inc (SYBX) is 1.24

What is the Market Cap of Synlogic Inc?

The market capitalization of Synlogic Inc (SYBX) is $16.49M

What is Synlogic Inc’s stock symbol?

The stock symbol (or ticker) of Synlogic Inc is SYBX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top